Table 2 Adjuvant chemotherapy in relation to clinicopathological parameters

No follow up, n

1

0

1.000

2

0

1.000

Received neoadjuvant treatment, n

0

2

0.204

0

0

Sex

0.253

1.000

Female, n (%)

31 (61%)

20 (39%)

25 (71%)

10 (29%)

Male, n (%)

29 (49%)

30 (51%)

22 (73%)

8 (27%)

Age at surgery, years. M (IQR)

69 (62–73)

66 (60–70)

0.260

67 (62–72)

67 (56–71)

0.441

Tumour origin

0.002

0.316

Pancreas, n (%)

16 (35%)

30 (65%)

Distal bile duct, n (%)

30 (67%)

15 (33%)

Ampulla of Vater, n (%)

14 (74%)

5 (26%)

35 (69%)

16 (31%)

Duodenum, n (%)

12 (86%)

2 (14%)

Tumour size, mm. M (IQR)

30 (22–37)

30 (25–35)

0.702

23 (13–40)

30 (24.5-40)

0.690

Tumour grade

0.555

0.783

Well/moderate, n (%)

21 (50%)

21 (50%)

24 (75%)

8 (25%)

Poor, n (%)

39 (57%)

29 (43%)

23 (70%)

10 (30%)

Lymph nodes

0.531

0.013

Uninvolved (N0), n (%)

20 (61%)

13 (39%)

30 (86%)

5 (14%)

Involved (N1-N2), n (%)

40 (52%)

37 (48%)

17 (57%)

13 (43%)

Margins

0.452

0.230

Uninvolved, n (%)

5 (71%)

2 (29%)

11 (61%)

7 (39%)

Involved or unknown, n (%)

55 (53%)

48 (47%)

36 (77%)

11 (23%)

Perineural growth

0.362

0.229

No, n (%)

16 (64%)

9 (36%)

35 (78%)

10 (22%)

Yes, n (%)

44 (52%)

41 (48%)

12 (60%)

8 (40%)

Growth in lymph vessels

0.223

1.000

No, n (%)

16 (46%)

19 (54%)

21 (72%)

8 (28%)

Yes, n (%)

44 (59%)

31 (41%)

26 (72%)

10 (28%)

Growth in blood vessels

0.312

1.000

No, n (%)

37 (51%)

36 (49%)

43 (72%)

17 (28%)

Yes, n (%)

23 (62%)

14 (38%)

4 (80%)

1 (20%)

Growth in peripancreatic fat

0.649

0.142

No, n (%)

15 (60%)

10 (40%)

34 (79%)

9 (21%)

Yes, n (%)

45 (53%)

40 (47%)

13 (59%)

9 (41%)

T-stage

0.240

0.301

T1, n (%)

2 (67%)

1 (33%)

5 (100%)

0

T2, n (%)

4 (33%)

8 (67%)

10 (83%)

2 (17%)

T3, n (%)

42 (54%)

36 (46%)

18 (72%)

7 (28%)

T4, n (%)

12 (71%)

5 (29%)

14 (61%)

9 (39%)

Year of surgery. M (IQR)

2007.5 (2004–2010)

2009 (2007–2010)

0.004

2006 (2003–2009)

2009 (2006.5-2010)

0.372